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Abstract
Background: The multifunctional receptor LRP1 has been shown to bind and internalize a large number of protein ligands
with biological importance such as the pan-protease inhibitor a2-macroglobulin (a2M). We recently identified A2ML1, a new
member of the a2M gene family, expressed in epidermis. a2ML1 might contribute to the regulation of desquamation
through its inhibitory activity towards proteases of the chymotrypsin family, notably KLK7. The expression of LRP1 in
epidermis as well as its ability to internalize a2ML1 was investigated.
Methods and Principal Findings: In human epidermis, LRP1 is mainly expressed within the granular layer of the epidermis,
which gathers the most differentiated keratinocytes, as shown by immunohistochemistry and immunofluorescence using
two different antibodies. By using various experimental approaches, we show that the receptor binding domain of a2ML1
(RBDl) is specifically internalized into the macrophage-like cell line RAW and colocalizes with LRP1 upon internalization.
Coimmunoprecipitation assays demonstrate that RBDl binds LRP1 at the cell surface. Addition of RAP, a universal inhibitor
of ligand binding to LRP1, prevents RBDl binding at the cell surface as well as internalization into RAW cells. Silencing Lrp1
expression with specific siRNA strongly reduces RBDl internalization.
Conclusions and Significance: Keratinocytes of the upper differentiated layers of epidermis express LRP1 as well as a2ML1.
Our study also reveals that a2ML1 is a new ligand for LRP1. Our findings are consistent with endocytosis by LRP1 of
complexes formed between a2ML1 and proteases. LRP1 may thus control desquamation by regulating the biodisponibility
of extracellular proteases.
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Introduction
The low density lipoprotein receptor-related protein-1 (LRP1) is
a member of the low density lipoprotein (LDL) receptor family of
endocytic receptors. LRP1 interacts with and internalizes a large
number of protein ligands, and plays an essential role in lipid
metabolism, protease/inhibitor homeostasis, and virus or toxin
entry [1,2]. Beside endocytosis, LRP1 can also regulate signaling
pathways [3]. More recently, LRP1 has been directly involved in
migration [4] and cancer progression [5]. LRP1 is essential for
embryonic development, as blastocysts fail to transform into
embryos after LRP1 targeted gene disruption in the mouse. The
biological importance of LRP1 has also been highlighted by the
generation of tissue-specific LRP1 knockout mice [6,7,8].
LRP1 is synthesized as a 600-kDa precursor protein which by
proteolytic processing matures into a 515-kDa chain (a chain) and
a 85-kDa chain (b chain). LRP1 has been initially described as an
endocytic receptor for apolipoprotein E and for the tetrameric
protease inhibitor a2-macroglobulin (a2M) [9,10,11]. Upon
formation of a complex consisting in a2M and a protease, a
conformational change within the C-terminal domain of each
a2M subunit results in the exposure of a previously hidden
receptor binding domain (RBD). Such an a2M molecule,
designated as the activated form, is able to bind LRP1, in contrast
to the native form that is not. LRP1 mediates clearance of the
a2M-protease complexes by endocytosis and lysosomal degrada-
tion. As a2M is also a cytokine carrier, LRP1 may also function as
a regulator of inflammation [12,13,14].
We recently identified a new gene of the a2-macroglobulin
family, A2ML1, and characterized the expression of the corre-
sponding protein, a2ML1, in the epidermis [15]. a2ML1 is
expressed by keratinocytes of the uppermost granular layer of the
epidermis, where it is secreted through the lamellar bodies into the
extracellular space. Distinct from a2M, which is tetrameric,
a2ML1 appears to be monomeric, but shares specific features of
the a2M family: it presents a broad-spectrum anti-protease activity
and is able to form covalent binding with proteases.
To better understand the role of a2ML1 in the epidermis, we
investigated whether a2ML1 can bind LRP1. LRP1 is expressed
by multiple cell types, and is especially abundant in hepatocytes,
vascular smooth muscle cells, and neurons. In a study using an
immunohistochemical approach, LRP1 expression was detected in
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epidermis [16], while another study reported the presence of
LRP1 in human epidermis and cultured keratinocytes [17].
In this study, we investigated the precise location of LRP1 in
human epidermis by immunohistochemistry and immunofluores-
cence using two different antibodies. LRP1 appears mainly present
inthegranularlayeroftheepidermisattheperipheryofthecells.We
show that the putative a2ML1 RBD domain (RBDl), comprised of
the 143 C-terminal residues, binds to LRP1 and is internalized with
this receptor in RAW 264.7 cells. The receptor-associated protein
(RAP), a protein chaperone that inhibits binding of many ligands to
LRP1, inhibits binding and internalization of RBDl. Down-
regulation of Lrp1 mRNA by siRNA reduces the internalization of
RBDl, demonstrating that LRP1 is required for RBDl endocytosis.
Comparative amino acid and structure analysis between the RBD
domains of a2M and a2ML1 together with competition experiment
suggest that the binding site of a2ML1 to LRP1 may be identical
from that of a2M.
Materials and Methods
Antibodies and Reagents
The following monoclonal (mAbs) or polyclonal antibodies were
used in this study: mouse 8G1 mAb (Calbiochem), which
recognizes the 515-kDa extracellular a chain of LRP1 (amino
acids 1–72), mouse 5A6 mAb (Calbiochem), which recognizes the
85-kDa intracellular b chain of LRP1, polyclonal goat anti-a2M
antibody (R&D Systems), polyclonal rabbit anti- pan desmocollin
antibody (Serotec), polyclonal rabbit anti-involucrin antibody
(BTI), anti-EEA1 mAb (BD Transduction Laboratories), anti-
GST mAb (Pierce), anti-actin mAb and MOPC IgG2 mAb
(Sigma). The polyclonal rabbit anti-corneodesmosin was described
elsewhere [18]. SiRNA duplexes were purchased from Qiagen
(MmLrp1-1 siRNA, MmLrp1-7 siRNA and Allstars negative
Control siRNA). Streptavidin peroxidase and streptavidin fluores-
cein were from Boehringer Mannheim. TRITC conjugate goat
anti-mouse antibody was from Immuonotech. Alexa 488 conju-
gate goat anti-mouse and 555 goat anti-rabbit antibodies were
from Invitrogen. GST-RAP was described elsewhere [19].
Activated human a2M (a2M-MA) was from BioMac.
Biological materials
All human skin samples were obtained from donors undergoing
plastic surgery (Dr JP Chavoin) after informed verbal consent, as
recommended by the local ethics committee (CHU Toulouse,
France), and in accordance with Helsinki principles.
Production of recombinant RBDl
A cDNA fragment encoding the last 143 amino-acids of a2ML1
(aa 1312–1454 GenBank NP_653271, denoted RBDl) was PCR-
amplified and subcloned into PGEX6p1 (Amersham Biosciences).
The construct was transformed into BL21-codonPlus bacteria
(Stratagene). The extraction of the recombinant GST-RBDl fusion
protein was essentially performed according to the online protocol
contributed by Dr. Chia Jin Ngee. Basically, after lysozyme
digestion, proteins from cell lysates were solubilized in 0.7%
Sarkosyl and 2% triton X-100 in 10 mM Tris-HCl, pH 8, 1 mM
EDTA, and 150 mM NaCl. RBDl was purified by affinity on a
glutathione sepharose column and eluted by 10 mM glutathione,
pH 8. The recombinant protein was dialyzed against PBS and
quantified using a standard BioRad assay. Using a similar
procedure, a cDNA fragment encoding 148 amino acids
positioned in the central bait region of a2ML1 (aa 586–734,
denoted CBD) was used to produce a GST fusion protein. All
plasmid constructs were checked by sequencing performed by
standard procedures.
Cell culture
The murine macrophage-like RAW 264.7 cell line was grown in
DME/Glutamax medium supplemented with 10% SVF and
antibiotics.
Immunoblotting
RAW cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.5,
150 mM NaCl, 10 mM EDTA containing 0.1% SDS, 1% Triton X-
100, 0.5% Na deoxycholate and a protease inhibitor cocktail
(Sigma)). Epidermal proteins were extracted with 40 mM Tris-HCl,
pH 7.5 and 10 mM EDTA containing 0.5% Nonidet P-40 and
protease inhibitors. Biochemical analysis of LRP1 expression was
performed by immunoprecipitation assays using either 8G1 mAb
(1 mg/ml) or 5A6 mAb (1 mg/ml). Incubation was performed
overnight at 4uC under agitation. Protein A/G sepharose beads
(Pierce) were then added and an additional incubation of 1 h was
performed at 4uC.AfterthreewashesinRIPAbuffer,Laemmlibuffer
without reducing agents was added to the sepharose beads. Samples
were analyzed by western blotting using standard procedures.
Binding experiments
RAW cells grown to 80% confluence in T25 flasks were washed
abundantly with OPTI-MEM medium and incubated with 5 mg/ml
of RBDl or control protein CBD for 2 h at 4uC under gentle
agitation. After extensive washes, cells were lysed on ice by adding
1 ml of RIPA buffer. Genomic DNA was disrupted by several
passages through a needle. Immunoprecipitation was carried out by
adding 1 mg of 8G1 or MOPC mAbs using the procedure described
above. The membrane was probed with anti-GST mAb (1:10 000).
In some experiments with RAP, the cells were preincubated or not
for 30 min at 4uC with GST-RAP at 5 mM before addition of RBDl
or CBD for 2 h at 4uC. Immunoprecipitation was carried out by
adding 1 mg of anti-GST mAb followed by western blot with anti-
GST. For competition experiment, RAW cells were preincubated
for 30 min at 4uC with a range of RBDl (0.05, 0.1, 0.5 and 1 mM) or
with GST (1 mM) before a2M-MA was added onto the cells at a
concentration of 0.015 mM and incubated for 2 h at 4uC. Bound
a2M-MA was immunoprecipitated with anti-a2M (0.5 ug/ml) and
detected with the same antibody by western blot.
Uptake experiments
RAW cells were plated 24 h before the experiments in 6-well
plates at a density of 400,000. Cells were washed with pre-warmed
OPTI-MEM medium and incubated with RBDl, GST alone, CBD
protein (each at 35 nM) or activated a2M-MA (14 nM) at 37uCf o r
different times.Cellswerethen washedabundantly andlysed in1 ml
of RIPA buffer. Immunoprecipitations were performed as described
before with anti-GST mAb (1 mg/ml) or anti-a2M antibody
(0.5 mg/ml). The immunoprecipitated proteins were analyzed by
Western blot with anti-GST or anti-a2M antibodies.
LRP1 gene silencing
siRNA transfection was performed according to the Qiagen
supplementary protocol for macrophage cell lines. Two mouse
specific Lrp1 siRNAs (Lrp1.1 and Lrp1.7) or negative control
siRNA (AllStars Negative Control) were transfected. The targeted
sequences of Lrp1 (NM_008512) are: (nt5945)CACGTTGGTTA-
TGCACATGAA(nt5965) for Lrp1.1 siRNA and (nt5498)CACCAA-
CAAGAAGCAGATTAA(nt5518) for Lrp1.7 siRNA. The negative
control siRNA had no target sequence. The day before
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transfected in triplicate using 50 nM siRNA with 6 ml of reagent
buffer (HiPerfect, Qiagen). Gene silencing was analyzed by
quantitative real time PCR 48 h after transfection. For RBDl
uptake quantification, triplicates were lysed in RIPA buffer and
pooled before immunoprecipitation with anti-GST. After precip-
itation of the sepharose beads, the supernatants were used as
loading controls to monitor total protein content by western blot
with an anti-actin mAb.
Real-time qPCR
Total RNA from triplicate wells was extracted using the RNeasy
extraction kit (Qiagen). Reverse transcription was performed via a
standard procedure, using 1.5 mg of total RNA and a mixture of
oligo(dT) and random primers. Two sets of primers were chosen
using Primer3 software [20] for the amplification of Lrp1 exons
41–42 (amplifying a 137 bp fragment) and exons 76–77
(amplifying a 105 bp fragment). Sequences were as follows: exons
41–42 forward 59-ACTTTGGGAACATCCAGCAG-39 and re-
verse 59-GGTGGATGTGGTGTAGCTTG-39; exons 76–77
forward 59-CCCTCCTACCACTTCCAACC-39 and reverse 59-
CCCAGTCGATAGCGATACC-39. A pair of primers specific for
the housekeeping gene mouse beta-2 microglobulin (B2m)
generating an amplicon of 166 bp (forward 59-ACGCCTGCA-
GAGTTAAGCAT-39 and reverse 59-GCTATTTCTTTCTGC-
GTGCAT-39) was used as the normalizer for each sample.
Amplifications were performed with the ABI prism 7300 Sequence
Detection System and analyzed with the corresponding software
(Applied Biosystems) using the qPCR ROX-&GO Green mix (MP
Biomedicals). All amplified products were checked by dissociation
curve analysis. Samples were analyzed in triplicate and quantified
using the comparative Ct method [21]. Threshold cycle (Ct) values
for Lrp1 were normalized to Ct values for B2m. The relative Lrp1
mRNA level (expressed in %) was calculated from the mRNA ratio
of either Lrp1 siRNA-transfected cells vs untransfected cells or
negative control siRNA-transfected cells vs untransfected cells.
Standard deviations were calculated using the methods of standard
propagation of error.
Immunohistochemistry and immunofluorescence
Immunohistochemistry was performed on formaline-fixed skin
samples embedded in paraffin using regenerator buffer S2368,
pH 9.0 and either the K5001 kit when using 8G1 mAb or the
Strept.ABC kit when using 5A6 mAb (both from DAKO). Samples
were incubated at room temperature with 8G1 mAb (2 mg/ml) and
with 5A6 mAb (10 mg/ml). Negative controls were incubated with
secondary antibody alone. For immunofluorescence, cryosections of
human skinsamples wereblocked inPBS,BSA 1%, Tween-20 0.2%
for 1 h. All incubations and washes were performed at room
temperature in the same blocking buffer. Incubations were as
follows: primary antibody (8G1 or 5A6 mAbs, 2 mg/ml) for 2 h,
Alexa 488 conjugate goat anti-mouse antibody (green) for 1h. For
double staining, the same procedure was followed by incubations
with polyclonal rabbit antibodies and then with Alexa 555 conjugate
goatanti-rabbitantibody(red).Imagingwasperformed usingaLeica
fluorescence microscope and NIS-Elements BR2.30 software.
Internalization of biotinylated RBDl and confocal
microscopy
Recombinant RBDl protein or control GST (150 mg each) were
incubated with NHS-Biotin (PIERCE) with a molar ratio biotin:
recombinant protein of 40:1 in 0.1 M NaHCO3, pH 8 for 1 h at
room temperature. The reactions were stopped by addition of L-
Lysine to a final concentration of 0.5 mM followed by an additional
incubation for 30 min. The proteins were then dialyzed against PBS
pH 7.4. Biotinylation was controlled by loading 1 mg of the proteins
on gels followed by western blotting with streptavidin-peroxidase.
RAW cells were plated on glass cover slips at a density of
50,000/cm
2. After overnight recovery, the cells were incubated in
the presence of 60 nM biotinylated protein in OPTI-MEM
medium for 30 min at 37uC or for 1h at 4uC. The cells were then
washed and fixed with methanol for 5 min at 220uC. Blocking
buffer containing streptavidin-fluorescein (2 mg/ml) was then
added for 1 h. For double labeling, incubation with 8G1
(2.5 mg/ml) or anti-EEA1 (1:200) mAbs followed by TRITC goat
conjugate anti-mouse antibody took place before labeling with
streptavidin-fluorescein. Analyses were performed by confocal
imaging. In experiments using RAP, the cells were preincubated
with 5 mM GST-RAP for 30 min at 37uC before addition of
biotinylated RBDl, followed by incubation for 30 min at 37uC. In
experiments with siRNA-transfected cells, biotinylated RBDl was
added to untransfected cells, mock siRNA or LRP1siRNAs-
transfected cells 48 h after transfection. The procedure described
above was then followed. Imaging was performed using a Leica
fluorescence microscope and NIS-Elements BR2.30 software.
Structure predictions and alignments
Secondary structure of RBDl was predicted using the New Joint
method-based PAPIA package (http://mbs.cbrc.jp/papia/papia.
html) and by comparison with the NMR structure of RBD of a2M
[22,23]. A 3D model of RBDl was built using as a template the 3D
structure 1BV8, which corresponds to human RBD, and by using
the DeepView-The Swiss-PdbViewer software (http://www.expasy.
org/spdbv/). RBD alignments were performed using the Multalin
algorithm (http://www-archbac.u-psud.fr/genomics/multalin.
html). Orthologs of a2ML1 were as follows: chimpanzee
(XP_520828), rhesus monkey (XR_014195), dog (XP_543824),
cow (translated from EST CB226612). Predicted cat and hedgehog
a2ML1 orthologs were translated from genomic sequences.
Results
LRP1 is expressed in the granular layer of the human
epidermis
To determine LRP1 expression in the course of keratinocyte
differentiation, we performed immunohistochemistry and immuno-
fluorescence analyses (Figure 1A–G). We used either 8G1 or 5A6
mAbs, which recognize the a chain and the b chain of LRP1,
respectively. Immunohistochemistry(A,C)andimmunofluorescence
(B, D) revealed that LRP1 is mainly expressed in the granular layer
of the epidermis. The granular layer is the uppermost layer of living
cells beneath the stratum corneum and is constituted by the most
differentiated keratinocytes. We also detected LRP1 in dermal
fibroblastswiththesamemAbs,a finding in agreementwithprevious
studies [17]. We then performed double staining with three well-
known markers for differentiation of epidermal keratinocytes,
namely corneodesmosin (late marker, cytoplasmic and secreted,
specific of the granular layer) (Figure 1E), involucrin (early marker,
cytoplasmic) (Figure 1F), and with the desmosome protein
desmocollin 1 (late marker, transmembrane, specific of the granular
layer) (Figure 1G). The labeling for involucrin and corneodesmosin
did not superimpose with that of LRP1 within keratinocytes of the
granular layer. Detection of the epidermal isoforms of the
transmembrane desmosome protein desmocollin [24] with a pan
anti-desmocollin antibody allowed detection of the desmocollin 2
and 3 isoforms in basal keratinocytes, and of the desmocollin 1
isoform in the keratinocytes of the granular layer (Figure 1G). As
A2ML1 Is a New Ligand of LRP1
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and polarized staining for desmocollin 1 within the granular layer
towards the upper face of the stratum corneum. Co-localisation of
LRP1 with desmocollin 1 within the granular layer suggested that
LRP1 is located at the periphery of keratinocytes.
Analysis of LRP1 by Western blot was carried out on protein
extracts from either epidermis or the macrophage-derived RAW
264.7 cell line, which is known to express LRP1 as a functional
receptor [25]. In RAW cells, but also in human epidermis both the
a chain and the intracellular b chain were detected after
Figure 1. Expression of LRP1 in human epidermis. Immunohistochemistry and immunofluorescence analyses on skin samples in the presence
of 8G1 (A, B) or 5A6 mAbs (C–G). A, the a chain of LRP1 labeling shows weak cytoplasmic staining in the spinous layers while it appears to locate at
the periphery in the upper layers of the epidermis. B, using immunofluorescence, the a chain of LRP1 labeling is detected in the granular layer of
epidermis. The dermis was also labeled. C and D, the b chain of LRP1 is associated within the granular layer of epidermis. The dermis was positive. A,
C, original magnification6200. B, D, bar, 15 mm. E–G, Double labeling for LRP1 and corneodesmosin (E), involucrin (F) and desmocollin (G). LRP1 does
not colocalize with corneodesmosin or involucrin but colocalizes with desmocollin 1 within keratinocytes of the granular layer. D, E, F, nuclei were
counterstained with TOTO. H, Biochemical analysis of LRP1 expression. The a chain and b chain of LRP1 were detected in RAW cells and in human
epidermis by immunoprecipitation. Lysates from RAW cells or 300 mg of epidermal proteins (epid.) were incubated with 8G1 or 5A6 mAbs or without
antibody (2). Standard immunoprecipitations were then applied. The blots were probed with the same antibodies. Under non-reducing conditions,
the dimers formed by IgH and IgL chains were detected.
doi:10.1371/journal.pone.0002729.g001
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(Figure 1H). Altogether, these findings suggest that LRP1 is a
functional receptor in the upper layers of the epidermis.
The RBD domain of a2ML1 is internalized into RAW cells
and binds to LRP1 at the cell surface
It has been shown that the RBD domain of a2M is solely
responsible for the binding of a2M-proteinase complexes to LRP1
[26][23]. Many studies of a2M binding to LRP1 have used
recombinant proteins that represent the carboxy-ends of a2Ms
expressed in bacteria [19,27,28]. By homology with the RBD
domain of a2M, we defined the potential RBD domain of a2ML1.
Thisdomain,denotedRBDl,wasproducedasaGST-fusionprotein.
We first asked whether the RBDl protein could be internalized into
RAW cells, as those cells havebeendescribed by othersasexpressing
LRP1 at high levels [25]. Uptake experiments were performed by
incubating RBDl, GST alone as a negative control, or the activated
form of a2M (a2M-MA) as a positive control, onto RAW cells at
37uC for different times. Immunoprecipitations of recombinant
proteins from the cell extracts were then analyzed. RBDl was
internalized in a time-dependent fashion into RAW cells, and this
was similar to the uptake of the activated form of a2M albeit with a
slower kinetic (Figure 2A). The GST protein alone as well as the
central bait domain of a2ML1 (recombinant protein CBD) were not
internalized. To confirm that RBDl uptake was specific and
mediated by endocytosis, we carried out, in parallel, an incubation
of RBDl in the presence of 0.4 M sucrose, which has been shown to
inhibit clathrin-dependent endocytosis [29,30] (Figure 2B). Addi-
tionally, to exclude the hypothesis that immunoprecipitated RBDl
only resulted from binding at the cell surface during incubation,
parallel incubations of RBDl were performed at 4uC. As shown in
Figure 2B, sucrose prevented the uptake of RBDl, supporting the
hypothesis that RBDl is internalized by endocytosis. When
incubation was performed at 4uC, RBDl was poorly detectable,
thus revealing that in our experimental conditions for RBDl uptake,
immunoprecipitated RBDl mainly corresponds to the protein that
has been internalized. It should be noted that the relative high level
of RBDl detected at 37uC as compared to the level of cell-associated
RBDl at 4uC may account for accumulation of the protein into the
cells before degradation. We then asked whether RBDl could be
coimmunoprecipitated with LRP1. Binding experiments were
performed by incubating RBDl onto RAW cells in serum-free
medium for 2 h at 4uC to prevent internalization, followed by
immunoprecipitation ofLRP1by8G1mAb.AsshowninFigure 2C,
RBDl was coimmunoprecipitated by 8G1 mAb, but not by the
irrelevant MOPC mAb. Moreover, the CBD protein did not
coimmunoprecipitate with the LRP1 antibody. Thus, the specific
Figure 2. Analysis of the interaction of RBDl with LRP1. A,
Uptake of RBDl by RAW cells. RAW cells were incubated or not (2) with
RBDl, a2M-MA as a positive control or GST as a negative control for the
indicated periods of time. Immunoprecipitations were carried out with
anti-GST or anti-a2M antibodies. Samples were analyzed by immuno-
blot with the same antibodies. RBDl was internalized in a time
dependant manner. As anticipated, the activated form of a2M was
internalized while GST was not. S, supernatant recovered from cell
culture medium after incubation. IgL indicates the light chain of
immunoglobulins. B, endocytosis-dependent uptake of RBDl. RAW cells
were incubated with RBDl in the presence or absence of 0.4 M sucrose
at 37uC, or at 4uC versus 37uC in parallel experiments for the indicated
periods of time. Immunoprecipitations were performed as described
above. Addition of sucrose or incubation at 4uC blocked the uptake of
RBDl. S1 and S2 are supernatants recovered from cell culture medium
after incubation of RBDl in the absence or presence of sucrose,
respectively. C, Binding of RBDl to LRP1. RAW cells were incubated in
the presence of RBDl or CBD for 2 h at 4uC. Aliquots of the supernatants
(S) werethen collectedandthecellswerelysed.Immunoprecipitationwas
performedusingtheantiLRP18G1mAb ortheMOPCantibodyascontrol.
Co-immunoprecipitated proteins were detected by Western blot using
the anti-GST antibody. RBDl was specifically co-immunoprecipitated by
anti-LRP1 antibody. IgH and IgL indicate the heavy and the light chains of
immunoglobulins. D, RBDl binding at the cell surface in the presence of
RAP. RAW cells were preincubated or not with GST-RAP for 30 min at 4uC
before addition of RBDl or CBD for an additional 2 h incubation at 4uC.
Immunoprecipitation and Western blot detection was performed using
the anti-GST mAb. RBDl, but not CBD, was found associated at the cell
surface in the absence of GST-RAP. Addition of GST-RAP inhibited RBDl
binding to the cells. S, supernatants loaded as control.
doi:10.1371/journal.pone.0002729.g002
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RBDl interacts with LRP1. To further demonstrate the specificity of
interaction between RBDl and LRP1, we analyzed the binding of
RBDl at the cell surface in the presence of RAP, a universal ligand
competitor for LRP1 [19,31]. In this experiment (Figure 2D), GST-
RAP at 5 mM was added onto the cells for 30 min at 4uCb e f o r e
addition ofRBDl or CBD.After 2 hoursofincubation at 4uC,RBDl
bindingatthecellsurfacewasclearlydetected.WhenGST-RAPwas
present, RBDl was no longer immunoprecipitated, supporting that
LRP1 was involved in RBDl binding at the cell surface.
The RBD domain of a2ML1 colocalizes with LRP1 upon
internalization in vivo
To confirm and investigate internalization of RBDl via LRP1,
we analyzed the binding and internalization of a biotinylated form
of RBDl onto RAW cells by confocal microscopy using
strepatavidin-fluorescein conjugate for detection. We first con-
firmed the binding of RBDl to the cell membranes by incubation
of the biotinylated RBDl at 4uC to prevent internalization. As
expected, cell membranes were labeled by the biotinylated RBDl
protein (Figure 3A, left panel). Incubation at 37uC for 30 min
induced a shift of the biotinylated RBDl from the cell membrane
to the cytoplasm of the cells (Figure 3A, right panel). The cluster
appearance of the labeling was suggestive of formation of
endosomal vesicles. A biotinylated control GST, when incubated
at 37uC, was not detectable in the cytoplasm of the cells (not
shown). Double staining with 8G1 mAb revealed that LRP1
colocalized with RBDl in intracellular vesicles (Figure 3B). When
double staining was performed with an anti-EEA1 mAb, RBDl
was also found to colocalize with EEA1, a marker of early
endosomes (Figure 3C). We noted that a similar clustering
appearance of LRP1 was observed when a2M-MA was incubated
on cells for 30 min at 37uC (Figure 3D, E). In another set of
experiments, internalization of biotinylated RBDl was compared
between cells that had been preincubated with 5 mM GST-RAP
for 30 min at 37uC and those that had not before incubation with
biotinylated RBDl for 30 min at 37uC (figure 3F, G). While RBDl
was strongly detected in the cytoplasm of the control cells, poor
labeling was observed within cells that had been preincubated with
GST-RAP. In conclusion, and consistent with the in vitro
experiments, our results indicate that RBDl is specifically
internalized into RAW cells by endocytosis and that LRP1 is
involved in this process.
Silencing Lrp1 with siRNA reduces the internalization of
the RBD domain of a2ML1
To investigate whether LRP1 is required for the uptake of
RBDl, we used a siRNA approach to downregulate Lrp1
expression in RAW cells. Cells were transfected with two mouse
Lrp1-specific siRNAs (Lrp1.1 and Lrp1.7), a negative control
siRNA (NC), or were untransfected (NT). Lrp1 abundancy was
assessed at the mRNA level by real time quantitative RT-PCR
using the relative quantity method and NT cells as the calibrator.
Both Lrp1-siRNAs significantly decreased Lrp1 mRNA level
(Figure 4A), while no significant change was observed in NC
cells. Western blot detection of LRP1 after immunoprecipitation
with the 8G1 mAb shows that the a chain of LRP1 was not
detectable in cells transfected with Lrp1.1-siRNA (Figure 4B).
RBDl uptake in siRNAs-transfected cells was analyzed both by
biochemical experiments (Figure 4C) and immunofluorescence
analysis (Figure 4D). As shown in Figure 4C, the internalization of
RBDl was significantly reduced in cells transfected with Lrp1-
siRNAs by comparison with the uptake of RBDl into non-
transfected cells (NT) or into cells transfected with NC siRNA. In
the same manner, the uptake of biotinylated RBDl was clearly
reduced in Lrp1 siRNAs-transfected cells as compared to NC-
transfected cells, and this was correlated with the reduced
expression of Lrp1 revealed by 5A6 mAb labeling (Figure 4D).
Figure 3. Analysis of internalization of biotinylated RBDl into
RAW cells. A, Representative pictures obtained with streptavidin-
fluorescein labeling. A membrane staining was pronounced when cells
were incubated with RBDl for 1 h at 4uC. A cytoplasmic staining with
punctuate appearance was observed when cells were incubated with
RBDl for 30 min at 37uC. B,C, confocal pictures of individual cells
depicting double staining with streptavidin-fluorescein and with either
8G1 mAb (B) or anti-EEA1 mAb (C) coupled withTRITC conjugate anti-
mouse antibody. RBDl co-localized with LRP1 and with EEA1 in the
cytoplasm. D, E, Immunofluorescence labeling of LRP1 with 8G1 mAb
followed by Alexa-488 conjugate anti-mouse antibody on RAW cells
either untreated (D) or incubated with a2M-MA (E) for 37uC at 30 min. A
cytoplasmic staining with clustering appearance was observed when
cells were incubated with a2M-MA. F, G, streptavidin-fluorescein
labeling with TOTO nuclear counterstain of cells preincubated or not
with GST-RAP for 30 min at 37uC before addition of biotinylated RBDl
for 30 min at 37uC. The biotinylated RBDl was poorly internalized into
the cells in the presence of GST-RAP. Pictures were taken with the same
time exposure (137 ms). Bars, 5 mm.
doi:10.1371/journal.pone.0002729.g003
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PLoS ONE | www.plosone.org 6 July 2008 | Volume 3 | Issue 7 | e2729Figure4.AnalysisofRBDlinternalizationinLrp1-deficientcells.RAWcellsweretransfectedornot(NT)withoneofthetwoLrp1-siRNAs,Lrp1.1or
Lrp1.7, or with an unrelated siRNA as negative control (NC). 48h after transfection, Lrp1 mRNA was determined by real time qPCR (A), at the protein level
(B) or the cells were challenged for RBDl uptake (C, D). A, Lrp1 mRNA is reduced in Lrp1-siRNAs transfected cells. B, LRP1 is down-regulated at the protein
level in Lrp1-siRNA transfected cells. Immunoprecipitation of the a chain was performed using 8G1 mAb. The a chain was detectable in NT and NC cells
but not in Lrp1.1-siRNA cells. C, RBDl uptakeby LRP1-deficient cells is reduced. The cells were incubated with RBDl for 20 or 45 min. Uptake of the protein
was analyzed by immunoprecipitation followed by immunoblot with the anti-GST mAb. S, supernatant recovered from cell culture medium after
incubation. Total protein contents were monitored by Western blotting with a b-actin antibody. The blot shown was representative of two independent
transfections. D, Internalization of biotinylated RBDl into Lrp1-deficient cells is compromised. NC siRNA-transfected cells, Lrp1.1 and Lrp1.7 siRNA-
transfected cells were incubated with biotinylated RBDl for 30 min at37uC. Pictures depict streptavidin-fluorescein labeling (green) or anti-LRP1 5A6 mAb
labeling (red) with TOTO nuclear counterstain. Bar, 10 mm. Time exposures were 130 ms for overall pictures.
doi:10.1371/journal.pone.0002729.g004
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PLoS ONE | www.plosone.org 7 July 2008 | Volume 3 | Issue 7 | e2729Figure 5. Predicted structure of RBDl. A, Comparison of the NMR-determined secondary structure for human a2M RBD (according to reference
23) with the predicted secondary structure for human a2ML1 RBDl. The heavy lines with the letter ‘‘BS’’ indicate regions of b sheet conformation and
the dotted lines indicate regions of a-helical conformation (black color for a2M and grey color for a2ML1). The a-helix region of a2M RBD is assumed
to trigger binding to LRP1. The two lysine residues (Lys1370 and Lys1374) are underlined. In a2ML1 RBDl, two distinct a-helices (denoted 1 and 2) are
predicted, and the three lysine residues surrounding those regions are underlined. The S4 b-sheet is missing while the S5 b-sheet is only predicted by
the method of Chou-Fasman. A hypothetical 3D model of RBDl was built using the 3D structure 1BV8 (human RBD) as template. The major helix
regions are labeled in red and the b-strands are labeled in blue. Lysine residues (Lys1370 and Lys1374 for 1BV8, and Lys1392–1393 for RBDl) are
labeled in green. B, a2M-MA binding at the cell surface in the presence of RBDl. RAW cells were preincubated or not (lane 1) with RBDl (lanes 2
(0.05 mM), 3 (0.1 mM), 4 (0.5 mM), 5 (0.5 mM)) or with 1 mM of GST protein (lane 6) for 30 min at 4uC before addition of a2M-MA at 0.015 mM for an
additional 2 h incubation at 4uC. Immunoprecipitation and Western blot detection was performed using anti-a2M antibody. RBDl competes for a2M-
MA binding in a dose-dependent manner. C, Multalin RBD alignments between representative a2M members, human a2ML1 and predicted orthologs
of a2ML1. The dotted lines indicate the a-helix domains and lysine residues are marked by asterisks.
doi:10.1371/journal.pone.0002729.g005
A2ML1 Is a New Ligand of LRP1
PLoS ONE | www.plosone.org 8 July 2008 | Volume 3 | Issue 7 | e2729Altogether, these data demonstrate that LRP1 is required for
RBDl internalization by RAW cells.
Comparative structure analysis and competition assay
between a2ML1 and a2M suggest a similar mechanism
for binding to LRP1
RBD of a2M contains two lysine residues that are important for
binding to LRP1 [27,28,32,33]. These two lysine residues are
highly conserved among macroglobulins of the a2M family [28],
suggesting a common mechanism for binding to LRP1. Remark-
ably, a2ML1 lacks the two corresponding lysine residues.
Therefore we attempted to define a predicted structure of RBDl
As represented in Figure 5A, the predicted secondary structure of
RBDl shows overall similarity with the RBD structure. Distinc-
tively, the major a-helix segment containing the two key lysine
residues in a2M is missing in a2ML1, while two distinct a-helix
domains (denoted a-helix 1 and a-helix 2) are located between the
BS3 and BS6 b-sheets. A hypothetical 3D model of RBDl was
built using as template the 3D structure 1BV8, which corresponds
to human RBD. As represented in Figure 5A, the RBDl 3D model
closely resembles the 3D structure of human RBD, suggesting that
both proteins may bind to the same binding site of LRP1. To
adress this question, we analyzed the binding of a2M-MA at the
surface of RAW cells in the presence of increasing amounts of
RBDl. In this experiment, RBDl (0.05, 0.1, 0.5 and 1 mM) was
added onto the cells for 30 min at 4uC before addition of a2M-
MA at 0.015 mM followed by an additional incubation for 2 hours
at 4uC. RBDl reduced the binding of a2M-MA in a dose-
dependent manner (Figure 5B), suggesting that RBDl competed
for a2M-MA binding to LRP1. GST protein at 1 mM had no
significant effect on a2M-MA binding.
The Alignment of RBD sequences of A2M proteins and predicted
A2ML1 orthologs allowed us to delineate regions conserved among
both groups from group-specific regions (Figure 5C). For example,
the regions that constitute the BS3 and BS7 b-sheets are highly
conserved in all sequences. In contrast, the a helical domains are not
conserved between the two groups. Notably, the predicted a-helix 1
is conserved in all A2ML1 orthologs. Interestingly, the two lysine
residues positioned in tandem in close vicinity with the a-helix 1 are
conserved, suggesting that these residues may be important for the
binding to LRP1.
Discussion
In this study, we demonstrate that the Receptor Binding
Domain of a2ML1 (RBDl) interacts with and is internalized by
LRP1. By down-regulating Lrp1 expression, we show that LRP1 is
necessary for RBDl internalization. Our finding suggests that
a2ML1, like many other macroglobulins, is a ligand of LRP1.
Distinctively, a2ML1 misses the exposed a helix region of the
RBD domain of a2M that contains the two lysine residues
implicated in binding to LRP1. However, the predicted 3D model
of RBDl indicates that a2ML1 may bind to the same site of LRP1
than a2M does [33]. Indeed, RBDl contains a distinct, and
conserved, predicted a-helical region of which two lysine residues
are positioned in close vicinity. In the future, it will be interesting
to further delineate the region of RBDl required for binding to
LRP1.
Thus far, the expression of LRP1 in the epidermis has been
controversial [16,17]. Here, we validate the presence of LRP1 in
human epidermis. Using immunohistochemistry and immunoflu-
orescence, we found that LRP1 is expressed in the granular layer
of epidermis where it appeared to locate at the plasma membrane.
Previously, Birkenmeir et al had used immunofluorescence labeling
and found expression of LRP1 throughout the epidermis with
pronounced labeling in the basal layer of epidermis [16,17]. The
discrepancy with our immunohistochemistry and immunofluores-
cence analyses may be explained by the use of different antibodies.
However, the mAb used by Birkenmeir is no longer commercially
available. We believe that the concordant staining we obtained
with both the 8G1 and 5A6 mAbs support our conclusions. In
agreement with Birkenmeir, we found by immunofluorescence
analysis that LRP1 was expressed in the cytoplasm of actively
proliferating primary keratinocytes grown in vitro. Also, we
observed that LRP1 labeling was more intense at the periphery
of the cells when keratinocytes were induced to differentiate by
48 h exposure to 1.5 mM calcium (our observations). It will be
interesting to study the regulation of LRP1 expression during the
differentiation of keratinocytes.
We have previously shown that a2ML1 is expressed specifically
in the granular layer of keratinocytes and is secreted into the
extracellular space between the granular layer of keratinocytes and
the uppermost layer of corneocytes [15]. In vitro, a2ML1 inhibits
diverse proteases and particularly, we have shown that a2ML1
binds to the kallikrein KLK7, a chymotrypsin-like protease
important for desquamation [15]. While a role of LRP1 in the
epidermis remains to be determined, it is tempting to speculate
that LRP1 might have a role in the endocytosis of complexes
formed by a2ML1 and proteases such as KLK7 or other members
of the kallikreins.
An additional role for LRP1 in epidermis may be to regulate the
activity of some lipases. It is known that LRP1 plays an important
role in lipid metabolism by binding lipoproteins (or chylomycron
remnants) generated by hydrolysis of triglycerides by lipoprotein
lipases [6,34,35]. In addition, LRP1 also binds directly the lipases
that process triglycerides and subsequently mediates catabolism of
these lipases [36,37,38]. In the epidermis, extracellular lipids such
as ceramides, cholesterol, fatty acids, and cholesterol esters, are
essential for the barrier function (for review [39]). Of interest are
three new genes we have recently identified which encode putative
secreted hydrolases specifically expressed in the epidermis [40].
These newly identified lipases are strong candidates for the
extracellular hydrolysis of triglycerides in the intercellular space of
the stratum corneum. In the future, it will be of particular interest
to analyze whether LRP1 can regulate the activity of theses lipases.
In conclusion, we have shown that LRP1 can mediate
internalization of the RBD domain of a2ML1, suggesting that
complexes formed by a2ML1 with proteases may undergo
endocytosis via LRP1, a mechanism that could contribute to
regulate desquamation. Furthermore, we revealed a new,
unknown function for LRP1 in epidermis, which we assume to
be crucial in view of the biological importance of this
multifunctional receptor in other tissues.
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